Commack, NY

NY, Aug. 14, 2025 (GLOBE NEWSWIRE) - Scienture Holdings, Inc. (Nasdaq: SCNX) ("Scienture" or the "Company"),

a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians

and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today

announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 3,225,000 shares

of common stock at an offering price of $1.20 per share, in a registered direct offering. The gross proceeds for the offering are expected

to be approximately $3.9 million before deducting placement agent fees and other offering expenses. This offering is expected to close

on August 15, 2025, subject to customary closing conditions.

Group LLC is acting as sole placement agent in connection with the offering.

offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289198), previously filed with

the U.S. Securities and Exchange Commission (the "SEC") on August 1, 2025, and declared effective on August 8, 2025. The

shares may be offered only by means of a prospectus. A prospectus supplement and an accompanying prospectus relating to the offering

will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, copies of the prospectus

supplement and accompanying prospectus, relating to the offering may also be obtained by contacting Maxim Group LLC, at 300 Park Avenue,

16th Floor, New York, NY 10022, Attention: Prospectus Department, or by telephone at (212) 895-3745 or by email at syndicate@maximgrp.com.

press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale

of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration

or qualification under the securities laws of any such state or other jurisdiction.

Scienture Holdings, Inc.

HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company

focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market

needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals

who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare

systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and

more information please visit www.scienture.com.

press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities

laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical

are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange

Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking

statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry,

our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management

team's expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch and

the success those products may have in the marketplace. In addition, any statements that refer to projections, forecasts or other characterizations

of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify

forward-looking statements by the following words: "anticipate," "believe," "continue," "could,"

"estimate," "expect," "intend," "may," "ongoing," "plan," "potential,"

"predict," "project," "should," "seek," or the negative of these terms or other similar

expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject

to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially

different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on

any forward-looking statements. These risks include the Company's ability to satisfy closing conditions for the registered direct

offering; risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such

funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of

our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged

violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may

be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most

recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking

statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided